Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
09/17/2020 - 07:00 AM
HOUSTON , Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. Peter L. Hoang , will present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020 .
CONFERENCE DETAILS
Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date: Tuesday, Sept. 22 , 2020 1:40-2:20 p.m. ET
Live webcasts of the presentation will be accessible from the Investors markertherapeutics.com
About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts .
http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301132782.html
SOURCE Marker Therapeutics, Inc.
MRKR Rankings
#4373 Ranked by Stock Gains
MRKR Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Consumer Services, Other Consumer Services, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Jacksonville
About MRKR
tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). the company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer t-cells and helper t-cells to destroy cancer cells, and they are designed to work with 80% of the population. tapimmune is advancing two clinical stage t-cell vaccine candidates in multiple phase ii and phase ib/iia clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from fda fast track and orphan disease designation. the company is working in collaboration with industry and clini
